Posts

Showing posts with the label tatachemicals

Big movers on D-Street: What should investors do with Star Health, M&M and Tata Chemicals?

Image
[hfe_template id='11223'] [ad_1] Equity indices ended lower on Tuesday as a fag-end sell-off wiped out early gains amid a mixed trend in global markets. The 30-share Sensex declined 188 points to settle at 74,482 and the Nifty dipped 38 points to finish at 22,604. Stocks that were in focus include names like Star Health, which rose 1.69%, M&M, which increased 4.63%, and Tata Chemicals, whose shares declined 2.49% on Thursday. Here's what Riyank Arora, Technical Analyst at Mehta Equities, recommends investors should do with these stocks when the market resumes trading today. Star Health After making the high around 675 in Sept 2023, price has witnessed a bear run to make the low of 510 odd levels. Lower Top Lower Bottom pattern is formed as sellers were having upper hand over bulls. From the lows, stock has given some pull back and in the last two months stock is moving in the range of 535-595, breakout from the range will give further 20-30% move. For the long te...

Tata Chemicals shares fall over 4% on first-ever quarterly loss in nine years; Kotak Equities screams sell

Image
[hfe_template id='11223'] [ad_1] Shares of Tata Chemicals fell 4.5% to the day’s low of Rs 1,050 on BSE in Tuesday’s trade after the company reported its first-ever quarterly loss in nine years, hurt by a one-time charge incurred in its UK operations along with lower prices and demand for soda ash. Kotak Institutional Equities (KIE) recommended a ‘sell’ rating on the stock with a target price of Rs 770, which suggests a downside of nearly 29%. Tata Chemicals reported a consolidated net loss of Rs 850 crore in the quarter ended March 31, compared to a profit of Rs 709 crore a year ago. “The company reported weak earnings for 4QFY24, as expected, amid pricing pressure on soda ash across geographies. Earnings seem likely to remain near current run-rates through most of FY2025 in the context of continued oversupply; the large impairment charge in the UK is perhaps an indication,” said a report by Kotak Institutional Equities. The primary reason for the earnings to stay near ...